Share

'Animal pharm' catches Wall Street's attention

Overland Park - Cancer drugs for cats, pain relief for dogs, diarrhoea drugs for hogs and hormones for dairy cattle: The "animal pharm" industry is increasingly drawing the interest of Wall Street investors.

One of the newest companies to market in the emerging sector, California-based Jaguar Animal Health , notified the Securities and Exchange Commission in late August of intent to launch an initial public offering valued up to $70 million for development of gastrointestinal products for pets and livestock.

Jaguar said it launched its first commercial product, a drug to treat diarrhoea in calves, last week.

Analysts say interest in the growing sector is strong despite risks such as drugs that do not perform as expected.

"There is a a lot of enthusiasm for animal health," said Tim Lugo, an analyst at William Blair & Company, which has helped manage two recent animal health IPOs. "Vets in general are starving for new innovative therapies."

The animal health industry globally is pegged at $92bn to $102bn, with the subsector of animal medicines and vaccines seen at $22bn annually, according to a report by Technology Acceleration Partners, a private capital development firm targeting animal health, food and agriculture ventures.

From 2011 to 2016, the animal medicines and vaccines sector is expected to grow by 5.7% per year, the report states.

Investors like the fact that regulatory approval of products for animals can move faster at less cost than with drugs for people. While a drug for humans can take 10 years and more than $1bn to develop, one for animals can reach market in half that time for about $10m, industry experts said.

Until 18 months ago, animal drug development companies were largely off the radar screen, either divisions of much larger human-focused pharmaceutical companies, with products and profit streams secondary to the parent operations, or start-ups struggling for cash.

That changed in January 2013 when Pfizer spun off its animal health business Zoetis, raising $2.2bn. Shares have climbed more than 40% since then, to around $38.

One of Zoetis' hottest draws is a vaccine for pregnant hogs to ward off a virus that has killed millions of newborn pigs in the United States.

With Zoetis laying the groundwork, several other animal health companies have stretched out a hand to Wall Street, seeking capital for research and drug development.

Phibro Animal Health of New Jersey made a $200m offering in April and saw shares rise 31% through October. And in June, Parnell Pharmaceuticals Holdings of Overland Park, Kansas, raised about $50m for a portfolio including bone regeneration products for dogs.

Stan Baker, a lawyer for the firm of Husch Blackwell, which provides legal counsel for animal health companies, called the industry's rise "explosive."

"There was nothing, and then lo and behold we have an animal health space," he said. "All of a sudden people are going, 'Wow.' "

Pampered pets

A rising world population and increased wealth are boosting demand for animal health products, industry experts say. The drugs being developed help keep livestock healthy and can extend the lives and well-being of the pets people want to pamper.

Still, risks are real. In August, shares in newly minted public company Kindred Biosciences plunged following a failed field study on a new product for treating dogs with osteoarthritis. The company, which saw net proceeds of roughly $56 million from its December 2013 IPO, spent about $4m developing the drug before determining it would not work.

That did not deter Kansas City, Kansas-based Aratana Therapeutics Inc. from announcing on September 16 its aim to raise more than $41m in its third public offering in less than 18 months. Four-year-old Aratana has already raised more than $200m from public market investors since its June 2013 IPO.

Industry observers say it is too early to tell how well the animal health companies will do in the public investment spotlight, since few of them have meaningful track records.

"Is it a bubble? Maybe," said Technology Acceleration's chief executive officer, Michael Helmstetter. "We'll know in the next few years."

We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Rand - Dollar
18.88
+0.3%
Rand - Pound
23.86
+0.2%
Rand - Euro
20.37
+0.3%
Rand - Aus dollar
12.32
+0.1%
Rand - Yen
0.12
+0.2%
Platinum
908.05
0.0%
Palladium
1,014.94
0.0%
Gold
2,232.75
-0.0%
Silver
24.95
-0.1%
Brent Crude
87.00
+1.8%
Top 40
68,346
0.0%
All Share
74,536
0.0%
Resource 10
57,251
0.0%
Industrial 25
103,936
0.0%
Financial 15
16,502
0.0%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE
Government tenders

Find public sector tender opportunities in South Africa here.

Government tenders
This portal provides access to information on all tenders made by all public sector organisations in all spheres of government.
Browse tenders